Albany Molecular Research, Inc. (AMRI) Receives Approval of Preliminary Injunction Against Dr. Reddy’s Laboratories Ltd.

ALBANY, N.Y.--(BUSINESS WIRE)--AMRI (NASDAQ: AMRI) today announced that its motion for a preliminary injunction to prevent Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (Dr. Reddy’s) from the commercial distribution of generic versions of Allegra-D® 24 Hour (fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg) Extended-Release Tablets in the Unites States has been granted.
MORE ON THIS TOPIC